Medivation’s Buy Rating Reaffirmed at Chardan Capital (MDVN)
Medivation (NASDAQ:MDVN)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a note issued to investors on Monday, AnalystRatingsNetwork.com reports. They currently have a $100.00 target price on the stock. Chardan Capital’s price target would suggest a potential upside of 25.63% from the stock’s previous close.
In other Medivation news, CFO Clarence Patrick Machado unloaded 40,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $75.43, for a total value of $3,017,200.00. Following the transaction, the chief financial officer now directly owns 30,830 shares in the company, valued at approximately $2,325,507. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. raised their price target on shares of Medivation to $124.00 in a research note to investors on Monday. Separately, analysts at Sanford C. Bernstein downgraded shares of Medivation to a “market perform” rating in a research note to investors on Monday. Finally, analysts at Needham & Company downgraded shares of Medivation from a “buy” rating to a “hold” rating in a research note to investors on Monday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $91.73.
Medivation (NASDAQ:MDVN) opened at 79.60 on Monday. Medivation has a one year low of $41.89 and a one year high of $87.46. The stock has a 50-day moving average of $70.07 and a 200-day moving average of $61.3. The company’s market cap is $6.006 billion.
Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, January 30th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.29. Analysts expect that Medivation will post $-0.70 EPS for the current fiscal year.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.